Web Research
Web Research — What the Internet Knows
The Bottom Line from the Web
The financials show a struggling 2026 trough; the web shows why and how risky that trough actually is. CMS notified Elevance on March 2, 2026 of intent to suspend new enrollment in its Medicare Advantage prescription-drug plans starting March 31, prompting a $935M Q1 accrual and at least four shareholder securities-fraud investigations. Yet the same web feed also documents a Q1 2026 EPS beat ($12.58 vs $10.68 consensus, +14%), a guidance raise to $26.75+, a CFO-led leadership reshuffle taking over Carelon, and director-level open-market buying — the bull/bear gap is unusually wide.
What Matters Most
1. CMS intends to suspend Medicare Advantage drug-plan enrollment — and a $935M accrual was just booked. On March 2, 2026, CMS notified Elevance of intermediate sanctions that would suspend new enrollment in its Medicare Advantage Part D plans starting March 31, 2026; the stock fell more than 3% on the news. Q1 2026 results then included a $935M accrual for potential resubmission of Medicare Advantage risk-adjustment data covering 2015–April 2023. Source: Reuters, 2026-03-02 and 10-Q via StockTitan.
2. At least four securities-fraud investigations have been opened against Elevance. Kirby McInerney (April 2026), Bragar Eagel & Squire (April 20, 2026), Glancy Prongay & Murray (May 2025), and Bronstein, Gewirtz & Grossman (December 2025) have all opened investigations into possible securities-law violations tied to disclosures around Medicaid cost trends and the CMS sanction. Source: GlobeNewswire, 2026-04-23.
3. Q1 2026 broke the negative pattern: 14% EPS beat, raised full-year guide. Reported adjusted EPS of $12.58 vs $10.68 Zacks consensus on revenue of $50.18B; full-year 2026 adjusted EPS guide raised from "at least $25.50" to "at least $26.75", with management reaffirming at least 12% adjusted EPS growth in 2027 off a $25.75 baseline. Stock rose ~6.7% on the print. Source: Reuters, 2026-04-22 and Seeking Alpha.
4. Major leadership reshuffle: CFO Mark Kaye now also runs Carelon; Pete Haytaian out. Announced February 26, 2026 and effective May 4, 2026, EVP/President of Carelon Peter Haytaian transitions out (cited family commitments); CFO Mark Kaye expands his remit to oversee Carelon, and Felicia Norwood takes a consolidated Health Benefits role. The combined CFO + segment-president structure is unusual and concentrates execution risk on Kaye. Source: Elevance press release, 2026-02-26.
5. Lost $375M Medicare star-ratings lawsuit (August 2025). A federal judge in Texas rejected Elevance's challenge to CMS's star-ratings calculation; the company had argued improper rounding cost it at least $375M. Combined with the new Part D sanction, this signals a pattern of unfavorable Medicare regulatory outcomes. Source: Reuters, 2025-08-19.
6. Insiders are buying, not selling, into the weakness. A director made an open-market purchase of 3,000 shares on March 6, 2026 (Form 4 code "P"). A Yahoo Finance / Simply Wall St aggregation reported "bullish Elevance Health insiders loaded up on US$3.68m of stock" in the most recent twelve months. Insider ownership remains modest (0.1%–2.72% range across sources, totaling roughly $88M). Source: StockTitan Form 4, 2026-03-06, Yahoo/Simply Wall St.
7. Stock is in a deep drawdown — down ~40% from peak. Closing high of $544.37 on September 3, 2024; recently traded at ~$280–328 (depending on date snapshot). Down 19.4% over the trailing year, ~7% YTD. Trefis notes ELV's historical drawdown beta: in the 2008 GFC it fell 67% vs S&P −57%, and averages a 40% decline through major crashes. Source: MacroTrends, Simply Wall St.
8. Aggressive capital return continues during the trough. Q1 2026 alone returned $1.5B to shareholders, including 3.7M shares repurchased for $1.1B at an average price of $304.68; ~$5.6B remained authorized. Q2 dividend declared at $1.72/share (annualized ~$6.88, yield roughly 2%). Buyback yield ~1.9%. Source: Kavout, 2026.
9. Analyst targets cluster in the high-$300s, well below 2024 highs of $600+. Recent moves (April 2026): Mizuho cut to $350 from $413; Truist to $375 from $390; Jefferies trimmed to $391 from $395 (Buy maintained); JP Morgan raised to $397 from $394 (Overweight); Morgan Stanley equal-weight at $352. Wolfe Research upgraded to Outperform. Implied upside vs current ~$280–328 ranges from negligible to ~40% depending on shop. Marketbeat consensus PT $387.40. Source: GuruFocus / Benzinga / Marketbeat aggregations.
10. Carelon (services arm) is the strategic wedge — services revenue grew ~60% in 2025. Management refined the long-term enterprise margin target to 5%–6% at Q4 2025 and is positioning Carelon (CarelonRx + Carelon Services) as the diversification engine. CareBridge home-health acquisition (~$2.7B), Paragon Healthcare (Jan 2024), Granular Insurance from Alphabet's Verily (Feb 2025), and Centers Plan for Healthy Living (NY Medicaid LTSS) all build out the services and home-care footprint. Source: Motley Fool Q4 2025 transcript, Healthcare Finance.
Recent News Timeline
What the Specialists Asked
Insider Spotlight
Institutional ownership
Insider ownership
Retail ownership
Vanguard stake
The ownership picture is conventional for a large-cap insurer: Vanguard, BlackRock, and State Street dominate; insider skin-in-the-game is modest at roughly $88M aggregate but the recent direction (a director's open-market buy and a $3.68M aggregate insider purchase total) is mildly bullish into the drawdown.
Industry Context
The web research is consistent on three sector-wide headwinds investors should keep in mind when reading ELV's numbers:
- Medicaid cost trend post-redetermination. All publicly traded MCOs — Centene, Molina, Humana, UnitedHealth, Elevance — flagged elevated medical costs in 2024–2025 driven by higher acuity in retained members. Elevance's Medicaid operating margin guidance for 2026 sits near negative 1.75%.
- Medicare Advantage repricing. UnitedHealth cut 2026 guidance and projected a revenue decline; Molina's stock fell 20% on a similar warning. Elevance's MA membership is projected to decline in the high-teens percent in 2026 by design (intentional bid pricing).
- ACA enrollment unwind. More than 1M fewer Americans signed up for Obamacare plans for 2026 as enhanced premium tax credits expired; Jefferies has been actively re-modeling Elevance's exchange-segment dynamics.
- AI as a battleground in claims. Reuters notes AI deployment "on both sides of the tug-of-war" between providers seeking higher reimbursement and insurers wanting proof of medical necessity. Elevance's Klover analysis paints AI/data as core to its competitive playbook.
Source: Reuters sector coverage, Klover.ai analysis.
All figures in USD. Cited dates reflect article publication or event timestamp as captured in the source URL. Where two sources differ on a metric, both are presented.